Rubius Therapeutics, a Cambridge, MA-based biotechnology company creating a new class of cellular therapies, completed a $100m crossover financing.
The company intends to use the proceeds to accelerate the development of its portfolio of RCTs™ towards clinical proof-of-concept, and to enhance its manufacturing capacity and capabilities.
Founded by Flagship Pioneering in 2014 and led by Torben Straight Nissen, Ph.D., President, Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics™ (RCT™) products, which have the potential to provide clinical benefits to a wide range of patients across multiple therapeutic areas. These allogeneic, off-the-shelf products offer the additional advantage of extended stability and storage to allow for rapid, universal access by the medical community.
The company was co-founded by David Epstein, Executive Chairman of Rubius and Executive Partner of Flagship Pioneering, and Noubar Afeyan, CEO of Flagship Pioneering.